Cite
HARVARD Citation
Sun, R. et al. (2017). Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors). European journal of cancer. pp. 202-211. [Online].